Evidence map›Paper›PMID 41275292›Full record

ArticleStem cell research & therapy2025

Preventing the onset of diabetes with precision delivery of mesenchymal stem cells to the pancreas in a preclinical model.

Reza Yarani, Rosita Primavera, Shashank Chetty, Jing Wang, Simranjeet Kaur, Martin Haupt-Jorgensen, Flemming Pociot, Avnesh S Thakor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Reza Yarani *Department of Radiology, Interventional Radiology Innovation at Stanford (IRIS), Stanford University, Palo Alto, CA, 94304, USA.ORCID http://orcid.org/0000-0002-9892-1937
Rosita Primavera *Department of Radiology, Interventional Radiology Innovation at Stanford (IRIS), Stanford University, Palo Alto, CA, 94304, USA.
Shashank ChettyDepartment of Radiology, Interventional Radiology Innovation at Stanford (IRIS), Stanford University, Palo Alto, CA, 94304, USA.
Jing WangDepartment of Radiology, Interventional Radiology Innovation at Stanford (IRIS), Stanford University, Palo Alto, CA, 94304, USA.
Simranjeet KaurTranslational Type 1 Diabetes Research, Department of Clinical Research, Steno Diabetes Center, 2730, Copenhagen, Herlev, Denmark.
Martin Haupt-JorgensenDepartment of Pathology, Bartholin Institute, Rigshospitalet, Copenhagen University, 2200, Copenhagen, Denmark.
Flemming PociotTranslational Type 1 Diabetes Research, Department of Clinical Research, Steno Diabetes Center, 2730, Copenhagen, Herlev, Denmark. flemming.pociot@regionh.dk.
Avnesh S ThakorDepartment of Radiology, Interventional Radiology Innovation at Stanford (IRIS), Stanford University, Palo Alto, CA, 94304, USA. asthakor@stanford.edu.

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
A stem cell activated cryogel bioscaffold that restores islet bioenergetics while providing oxygen and nutrients at extravascular sites of transplantationR01DK129343 · NIDDK · STANFORD UNIVERSITY · PI Avnesh Sinh Thakor · 2022 to 2026
$2.8M
A novel approach for treating diabetes using pulsed focused ultrasound and intra-arterial delivery of mesenchymal stem cell based therapies directly into the pancreasR01DK119293 · NIDDK · STANFORD UNIVERSITY · PI THAKOR, AVNESH SINH · 2019 to 2023
$2.3M
Facilitating islet implantation and engraftment following transplantation using primed umbilical cord mesenchymal stem therapies and focused ultrasoundR01DK141802 · NIDDK · STANFORD UNIVERSITY · PI Avnesh Sinh Thakor · 2025 to 2026
$1.5M
Lundbeck Foundation grant R303-2018-3148National Institute of Diabetes and Digestive and Kidney Diseases,United States R01DK141802NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK119293NIDDK NIH HHS R01DK119293NIDDK NIH HHS R01 DK129343NIDDK NIH HHS R01 DK141802SDRC P30DK116074
6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) represent a promising regenerative therapy associated with anti-inflammatory, anti-apoptotic, and pro-proliferative properties. Despite their significant potential for treating diabetes, the clinical application of MSCs has been hindered mainly due to the low number of intravenously (IV) injected cells that successfully reach the pancreas.

methodsIn this study, we assessed the protective potential of adipose tissue-derived MSCs (AD-MSCs) in preventing the development of diabetes using a streptozotocin (STZ)-induced diabetic rat model. AD-MSCs were administered 4 h after STZ either via conventional IV injection or through direct intra-arterial (IA) administration into the pancreas. Healthy (no STZ, no MSCs) and diabetic (STZ, no MSCs) control groups were also included.

resultsOur proof-of-concept data indicate that IA administration of AD-MSCs allowed rats to maintain glycemic control and respond appropriately to glucose challenges following STZ treatment, comparable to healthy controls. In contrast, rats receiving IV AD-MSCs developed hyperglycemia and failed to respond adequately to glucose challenges. In vitro studies demonstrated that AD-MSCs can enhance the viability and function (i.e. insulin secretion) of injured islets.

conclusionLocal IA delivery of AD-MSCs into the pancreatic circulation effectively prevents the onset of diabetes in a preclinical rat model, highlighting the need for considering delivery techniques to ensure MSCs can reach their targets in vivo.

Indexed as

Diabetes Mellitus, ExperimentalMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPancreasAdipose TissueAnimalsBlood GlucoseDisease Models, AnimalMaleRatsRats, Sprague-DawleyStreptozocinBlood GlucoseStreptozocinGlycemic regulationIntra-arterial deliveryMesenchymal stem cellsPrecision deliveryType 1 diabetes

Identifiers

PMID41275292
PMCPMC12751359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.